Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Data
Clinical Data launches pharmacogenetic Warfarin response test on schedule
November 7th, 2006
Clinical Data, Inc. (CLDA) announced that its PGxHealth division, a provider of Therapeutic Diagnostics, has launched its PGxTest:Warfarin. The PGxTest:Warfarin is a pharmacogenetic test that measures variation in 2 genes. One gene, CYP2C9, metabolizes warfarin to an inactive metabolite; the second, VKORC1, encodes the enzyme that is the target of warfarin. Variants in these genes have been shown in multiple studies to correlate with warfarin dose requirements. A simple finger stick collects the sample for this test. Carol Reed, MD, senior vice president and chief medical officer of Clinical Data, said, "By acquiring certain intellectual property...
Source: Drug Law Weekly (2006-11-07)
|
